Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 27, 2021

Primary Completion Date

December 24, 2024

Study Completion Date

April 9, 2025

Conditions
Spinal Cord Injury
Interventions
BIOLOGICAL

MT-3921

Solution for infusion; Intravenous (IV)

BIOLOGICAL

Placebo

Solution for infusion; Intravenous (IV)

Trial Locations (23)

24014

Carilion Clinic, Roanoke

28203

Carolinas Rehabilitation, Charlotte

30912

Augusta University, Augusta

32308

Tallahassee Neurological Clinic, Tallahassee

39216

University of Mississippi Medical Center, Jackson

40536

University of Kentucky, Lexington

45219

University of Cincinnati, Cincinnati

49503

Spectrum Health, Grand Rapids

53226

Medical College of Wisconsin - Froedtert Hospital, Milwaukee

63110

Saint Louis University Hospital, St Louis

68198

University of Nebraska Medical Center, Omaha

78229

The University of Texas Health Science Center at San Antonio, San Antonio

78234

Brooke Army Medical Center in San Antonio, Houston

92868

University of California Irvine, Orange

97239

Oregon Health and Science University - Center for Health & Healing, Portland

B3H3A7

NSHA-Queen Elizabeth II Health Sciences Centre, Halifax

K1Y4E9

The Ottawa Hospital, Ottawa

820-8508

Japan Organization of Occupational Health and Safety SPINAL INJURIES CENTER, Izuka-shi

501-1194

Gifu University Hospital, Gifu

072-0015

Hokkaido Spinal Cord Injury Center, Bibai-shi

651-0073

Japanese Red Cross Kobe Hospital, Kobe

860-0008

National Hospital Organization Kumamoto Medical Center, Kumamoto

208-0011

Murayama Medical Center, Musashimurayama-shi

All Listed Sponsors
lead

Mitsubishi Tanabe Pharma America Inc.

INDUSTRY